StockMarketWire.com - N4 Pharma said a study conducted by Australia's University of Queensland had demonstrated the effectiveness of its delivery system for vaccines and cancer treatments.

The repeat study demonstrated that the company's product was capable of working in vivo when using multiple injections at certain doses.

N4 Pharma said it would now focus on improving the loading process to increase the consistency of the in vivo results.

Once successful, those improvements would allow it to move from exploratory collaborations to engage in full licensing discussions.

'The company remains well funded to do this next work,' it added.


At 9:14am: (LON:N4P) N4 Pharma Plc Ord 0.4p share price was -0.6p at 3.95p



Story provided by StockMarketWire.com